Beijing: China has rolled out a single-dose COVID-19 vaccine, touted to rival Johnson & Johnson’s one-jab shot. The vaccine was granted conditional approval on Sunday.
Phase-I clinical trials of this vaccine started on March 16, 2020. It is believed to provide protection after 14 days of inoculation and the effect of the vaccine is e
xpected to last at least six months.
The immune response can be increased 10 to 20 times if a second dose is taken 6 months after the first one, a Chinese media report said.
With the single-dose vaccine, China has approved five COVID-19 vaccines. The others are Sinovac, Sinopharm, CanSinoBio and another by Wuhan Institute of Biological Products.
As many as 500 million doses of this new Ad5-nCoV vaccine will be manufactured per year. It can be stored in normal refrigerators.
Also Read: Chinese COVID Vaccine On Hold, Sri Lanka To Use India’s Covishield For Now